Streetbeat News

Analyst Ratings

ACAD

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $25.0, down from $29.43. Analysts have recently lowered their price targets, reflecting changing market conditions. Despite this, ACADIA shows strong financial performance with a 46.44% revenue growth rate, a net margin of 13.8%, and a low debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:00 pm

ALGN

BLDR

IPX

OKUR

SITE

Top Wall Street analysts initiated coverage on several companies, including Align Technology, SiteOne Landscape Supply, OnKure Therapeutics, IperionX Limited, and Builders FirstSource. Notably, Builders FirstSource received a Buy rating from Goldman Sachs with a price target of $225.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 1:00 pm

SAGE

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Sage Therapeutics (NASDAQ:SAGE).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:59 pm

VRTX

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:58 pm

ARGX

Raymond James analyst Danielle Brill has reinstated a Strong Buy rating on argenx (NASDAQ:ARGX) and set a price target of $605.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:57 pm

SWKS

Barclays analyst Tom O'Malley has downgraded Skyworks Solutions (NASDAQ:SWKS) from Equal-Weight to Underweight and reduced the price target from $115 to $87.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:57 pm

ACAD

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:56 pm

XENE

Raymond James analyst Danielle Brill has reinstated an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and set a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:55 pm

AMT

Wells Fargo has downgraded American Tower (AMT) from Overweight to Equal-Weight and reduced its price target from $245 to $230.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:55 pm

AGIO

Raymond James analyst Danielle Brill has reinstated an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and set a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:54 pm